COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer
Neil H. Segal(Memorial Sloan Kettering Cancer Center), Josep Tabernero(Universitat de Vic - Universitat Central de Catalunya)
Cited by 12
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.4k
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
|Nature reviews. Cancer|2017|1k
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
|New England Journal of Medicine|2023|415